Monoclonal antibodies and engineered fusion proteins can be designed to specifically target and inhibit MMP-2 and MMP-9, and protein and peptide based inhibitors offer a targeted approach to inhibiting gelatinases, potentially improving treatment outcomes for CRC patients [174]. This evidence concerns the gene MMP9 and colorectal carcinoma.